Fezolinetant Changes Menopause Management, with JoAnn Vensko Pinkerton, MD
Pinkerton reflects on the breakthrough approval for the non-estrogen, non-hormonal daily oral drug earlier this year.
A Year of RSV Highs and Lows, with Tina Tan, MD
The Contemporary Pediatrics Editor-in-Chief reviews the pharmacological breakthroughs and epidemiological setbacks that defined RSV in 2023.
Gil Yosipovitch, MD: New Analysis of Data on Patient Satisfaction with Dupilumab for Prurigo Nodularis
This discussion with Dr. Yosipovitch covered findings presented at EADV 2023 on dupilumab and prurigo nodularis patients’ satisfaction.
Sophie Bakri, MD: Real-World Use of Faricimab in FARETINA-AMD Study
Real-world data from the FARETINA-AMD study show faricimab extended treatment intervals among eyes with nAMD.
Philip J. Mease, MD: New Data on Guselkumab for Psoriatic Arthritis Patients
This interview segment with Dr. Mease featured a discussion about data presented at ACR 2023 on guselkumab and patients with psoriatic arthritis.
Ricky Safer: What Clinicians Need to Know About PSC
Safer discusses how symptoms and quality of life often go unaddressed in the few clinician-patient interactions about primary sclerosing cholangitis.
Guillaume Lassailly: How Do We Value Bariatric Surgery in 2023?
Lassailly discusses the role of bariatric surgery versus weight-loss treatments like semaglutide for patients with MASH.
Raj Chovatiya, MD, PhD: Looking to the Future of Generalized Pustular Psoriasis Research
During this interview segment, Dr. Chovatiya further analyzed the updated National Psoriasis Foundation consensus statements for GPP and the future of treatment research.
Jean-Francois Korobelnik, MD, PhD: 96-Week PULSAR Data on Aflibercept 8 mg
At AAO 2023, Korobelnik provides insight into the efficacy and safety of aflibercept 8 mg in patients with nAMD observed over 2 years of the PULSAR study.
Edwin H. Kim, MD: Safety Data, Implications of New Oral Immunotherapy ADP101
During this segment of his interview, Dr. Kim went into the Harmony study data on safety of ADP101 presented at ACAAI as well as the implications of the research.
Edwin H. Kim, MD: Key Findings on Oral Immunotherapy ADP101
In this interview segment, Dr. Kim described some of the background and importance of the Harmony study data presented at ACAAI for patients with food allergy.
Marc Bonaca, MD, MPH: Benefit of Rivaroxaban for High-Risk Patients with PAD
Presented at AHA 2023, new analyses of VOYAGER PAD suggest the benefit of rivaroxaban plus aspirin for high-risk and complex populations with PAD.
Arun Sanyal, MD: Retatrutide and GLP-1 Agonists in MASLD
Sanyal discusses the makeup of retatrutide and its potential for patients with fatty liver disease and comorbid metabolic conditions.
The Future of Geographic Atrophy Treatment
Veeral Sheth, MD, MBA discusses the 3 improvements needed for the future of treating patients with geographic atrophy.
Safety of Therapies for Geographic Atrophy
Veeral Sheth, MD, MBA discusses safety signals reported with the use of approved therapies for geographic atrophy and the importance of real-world datasets.
Patient and Provider Perspective on Geographic Atrophy Therapies
Veeral Sheth, MD, MBA, discusses how clinicians are beginning to use these therapies and the patient reaction to the availability of treatments for GA.
Clinical Trial Evidence in Geographic Atrophy
Veeral Sheth, MD, MBA, discusses the clinical trial data that led to FDA approval of SYFOVRE and IZERVAY for geographic atrophy.
New Therapies for Geographic Atrophy
Veeral Sheth, MD discusses the two newly FDA-approved therapies for geographic atrophy: pegcetacoplan injection (SYFOVRE) and avacincaptad pegol (IZERVAY).
Symptoms and Manifestations of Geographic Atrophy
Veeral Sheth, MD, MBA describes the presentation of geographic atrophy in patients and how they are first affected by the disease.
Understanding Geographic Atrophy
David Lally, MD describes the hallmark features of geographic atrophy and how the disease develops over time.
Olivier Fakih, MD, MPH: Nationwide Data on Comorbidities of Axial Spondyloarthritis
This interview segment with Dr. Fakih featured a discussion about his team’s findings and their methodology on the topic of spondyloarthritis.
David Hunter, MBBS, PhD: Phase 3 Findings on Repeat TLC599 Injection for Osteoarthritis of the Knee
This discussion with Dr. Hunter covered the takeaways from his team’s phase 3 findings on treatment of osteoarthritis of the knee.
Ilias Alevizos, DMD, PhD: Safety, Future Development of Dazodalibep for Sjögren's Syndrome
During this interview segment, Dr. Alevizos discussed some of the implications of his team’s findings regarding dazodalibep.
Ilias Alevizos, DMD, PhD: Phase 2 Results on Dazodalibep for Sjögren's Syndrome
In this interview, Dr. Alevizos described the major takeaways from his team’s findings on this drug for Sjögren's Syndrome.
Women at 50% Greater Risk Progressing from Alcoholic Hepatitis to Cirrhosis than Men
Findings from The Liver Meeting show the impact of acute alcoholic hepatitis on progression to severe disease and risk of death among younger populations.
Jennifer Flemming, MD, FRCPC: Why Are More Women Developing Alcohol-Associated Liver Disease?
As more cases continue to disproportionately affect US women, an expert explains the biologic, sociocultural and clinical factors impacting the climb.
Prioritizing Gut Health, Bile Acid Research in Liver Disease Care
A trio of investigators discuss how research into bile acid interplay with the gut may lead to breakthroughs in treating conditions like NAFLD and NASH.
Bile Acids in Gut, Brain and Liver Health: What Do We Know?
A trio of scientists discuss the inception of a daylong Liver Meeting symposium around a little-understood subject in hepatic disease.
Jennifer I. Lim, MD: Effect of Faricimab on nAMD with Pigment Epithelial Detachments
Presented at AAO 2023, new data show dual Ang-2/VEGF-A inhibition with faricimab improved pigment epithelial detachment outcomes versus aflibercept.
Marco A. Zarbin, MD, PhD: Benefit of Faricimab for DME with BCVA ≤20/50
In a pooled subcohort analysis of YOSEMITE and RHINE, faricimab showed comparable vision outcomes with fewer injections than aflibercept in DME eyes with baseline BCVA of ≤ 20/50.
2 Clarke Drive Cranbury, NJ 08512